 |
32 Diseases |  |
11 Trials |
|
11 Trials |  |
1696 News |  |
| «12...9101112131415161718192021» |
- | Prezista (darunavir) / J&J, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: PEP2: Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis. (clinicaltrials.gov) - Apr 19, 2018
P1, N=58, Recruiting, Sponsor: Emory University
Not yet recruiting --> Recruiting
- || Prezista (darunavir) / J&J, Prezcobix (darunavir/cobicistat) / Gilead, J&J
Phase classification: ST.O.RE.: Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta) (clinicaltrials.gov) - Apr 2, 2018
P, N=337, Active, not recruiting, Sponsor: Janssen-Cilag S.p.A.
Not yet recruiting --> Recruiting Phase classification: P=N/A --> P
- ||||| rovafovir etalafenamide (GS-9131) / Gilead
New P2 trial, Monotherapy: Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus (clinicaltrials.gov) - Mar 20, 2018
P2, N=58, Not yet recruiting, Sponsor: Gilead Sciences
- | Prezista (darunavir) / J&J, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
New P1 trial: PEP2: Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis. (clinicaltrials.gov) - Mar 20, 2018
P1, N=58, Not yet recruiting, Sponsor: Emory University
- |||| Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) / Merck (MSD)
Trial primary completion date, Combination therapy: DRIVE-SHIFT: Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (clinicaltrials.gov) - Mar 3, 2018
P3, N=673, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Phase classification: P=N/A --> P Trial primary completion date: Feb 2018 --> Feb 2018
- ||| Prezista (darunavir) / J&J, Intelence (etravirine) / J&J, Isentress (raltegravir) / Merck (MSD)
Trial initiation date, Combination therapy: A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure (clinicaltrials.gov) - Feb 20, 2018
P4, N=545, Active, not recruiting, Sponsor: AIDS Clinical Trials Group
Trial primary completion date: Feb 2018 --> Feb 2018 Initiation date: Oct 2012 --> Feb 2013
- |||||| Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2- Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen (clinicaltrials.gov) - Feb 19, 2018
P2/3, N=100, Recruiting, Sponsor: Gilead Sciences
Initiation date: Oct 2012 --> Feb 2013 Active, not recruiting --> Recruiting
- | Prezista (darunavir) / J&J
Trial primary completion date, Combination therapy: Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-na (clinicaltrials.gov) - Jan 12, 2018
P4, N=120, Completed, Sponsor: Institut de M
Active, not recruiting --> Recruiting Trial primary completion date: Jan 2014 --> Mar 2011
- ||| New trial: RESIST-2: 2nd-line ART for HIV-2 Infection (clinicaltrials.gov) - Jan 9, 2018
P=N/A, N=150, Not yet recruiting, Sponsor: University of Washington
- | Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
Trial primary completion date: HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Jan 4, 2018
P1, N=20, Enrolling by invitation, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Trial primary completion date: Jan 2014 --> Mar 2011 Trial primary completion date: Dec 2017 --> Dec 2018
- | Selzentry (maraviroc) / ViiV Healthcare
Biomarker, Journal: Differential CD4 count increase and CD4: CD8 ratio normalization with maraviroc compared to tenofovir: a randomized trial. (Pubmed Central) - Dec 23, 2017
MVC resulted in less improvement in the CD4 : CD8 ratio driven by greater increase in CD4 cell count but smaller decline in CD8 cell count. Changes in soluble or cellular biomarkers of inflammation and immune activation were not different between MVC and TDF.
- | Prezista (darunavir) / J&J, zidovudine / Generic mfg., abacavir / Generic mfg.
Journal: Associations between antiretroviral use and subclinical coronary atherosclerosis. (Pubmed Central) - Dec 23, 2017
Among virally suppressed HIV-infected men with extensive ART exposure, no consistent associations between use of specific ART drugs and both subclinical coronary plaque presence and extent were apparent. Our findings support the hypothesis that, among virally suppressed persons, type of ART used is not in general a major determinant of subclinical coronary plaque risk.
- ||||| Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed: Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2- Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen (clinicaltrials.gov) - Dec 12, 2017
P2/3, N=100, Active, not recruiting, Sponsor: Gilead Sciences
Our findings support the hypothesis that, among virally suppressed persons, type of ART used is not in general a major determinant of subclinical coronary plaque risk. Recruiting --> Active, not recruiting
- ||| Prezista (darunavir) / J&J, Isentress (raltegravir) / Merck (MSD)
New trial: Bitherapy With the Combination of Raltegravir and Darunavir (BIRDi) (clinicaltrials.gov) - Nov 20, 2017
P=N/A, N=201, Recruiting, Sponsor: Asociacion para el Estudio de las Enfermedades Infecciosas
- Prezista (darunavir) / J&J, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion: QuaDar: Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy (clinicaltrials.gov) - Nov 6, 2017
P4, N=10, Completed, Sponsor: University of British Columbia
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Enrollment closed: TRULIGHT: Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (clinicaltrials.gov) - Oct 6, 2017
P3, N=224, Active, not recruiting, Sponsor: University Hospital, Tours
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Isentress (raltegravir) / Merck (MSD)
Trial completion, Enrollment change: RANIA: Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) (clinicaltrials.gov) - Aug 7, 2017
P2, N=11, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=100 --> 11
- ||||||| lamivudine / Generic mfg.
Trial completion, Head-to-Head: MOBIDIP: Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa (clinicaltrials.gov) - Jul 21, 2017
P3, N=265, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Active, not recruiting --> Completed | N=100 --> 11 Active, not recruiting --> Completed
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion: HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen (clinicaltrials.gov) - Jun 14, 2017
P4, N=44, Completed, Sponsor: Hospital Universitari Vall d'Hebron Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Prezista (darunavir) / J&J
Trial completion, Trial primary completion date, Monotherapy: MANET: Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS (clinicaltrials.gov) - Jun 2, 2017
P3, N=121, Completed, Sponsor: University of Liverpool
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Oct 2015 --> Jun 2016
- | Prezista (darunavir) / J&J, Isentress (raltegravir) / Merck (MSD)
Journal: Changes in markers of T cell senescence and exhaustion with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. (Pubmed Central) - May 24, 2017
There were no changes in markers of CD8+ T cell senescence after ART and no differential changes in all markers in ART groups. Senescent CD4+ and CD8+ T cells may have differential roles in HIV-1 pathogenesis.
- | Prezista (darunavir) / J&J
New P4 trial: Optimization of Darunavir Therapy and Dosage Recommendations (clinicaltrials.gov) - Apr 5, 2017
P4, N=150, Recruiting, Sponsor: Universit
- | Prezista (darunavir) / J&J, Prezcobix (darunavir/cobicistat) / Gilead, J&J
Phase classification: ST.O.RE.: Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta) (clinicaltrials.gov) - Mar 13, 2017
P=N/A, N=300, Active, not recruiting, Sponsor: Janssen-Cilag S.p.A.
Senescent CD4+ and CD8+ T cells may have differential roles in HIV-1 pathogenesis. Phase classification: P4 --> P=N/A
- ||||| Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) / Merck (MSD)
Enrollment closed, Combination therapy: DRIVE-SHIFT: Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (clinicaltrials.gov) - Mar 10, 2017
P3, N=660, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Phase classification: P4 --> P=N/A Recruiting --> Active, not recruiting
- | Prezista (darunavir) / J&J, Intelence (etravirine) / J&J, Isentress (raltegravir) / Merck (MSD)
Trial primary completion date, Combination therapy: A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure (clinicaltrials.gov) - Feb 17, 2017
P4, N=545, Active, not recruiting, Sponsor: AIDS Clinical Trials Group
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2018 --> Nov 2016
- Prezista (darunavir) / J&J, Intelence (etravirine) / J&J, Isentress (raltegravir) / Merck (MSD)
Trial primary completion date, Combination therapy: A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure (clinicaltrials.gov) - Jan 26, 2017
P4, N=545, Active, not recruiting, Sponsor: AIDS Clinical Trials Group
Trial primary completion date: Sep 2018 --> Nov 2016 Trial primary completion date: Dec 2016 --> Sep 2018
- Prezista (darunavir) / J&J
Trial completion: DARULIGHT: Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients (clinicaltrials.gov) - Jan 24, 2017
P2, N=100, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Trial primary completion date: Dec 2016 --> Sep 2018 Active, not recruiting --> Completed
- Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
Trial primary completion date: HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Jan 10, 2017
P1, N=20, Enrolling by invitation, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
- Trial primary completion date: TRULIGHT: Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (clinicaltrials.gov) - Jan 4, 2017
P3, N=250, Recruiting, Sponsor: University Hospital, Tours
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2016 --> Aug 2017
- |||||| Tybost (cobicistat) / Gilead, Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (clinicaltrials.gov) - Dec 5, 2016
P2/3, N=100, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Dec 2016 --> Aug 2017 Active, not recruiting --> Recruiting
- |||| Prezista (darunavir) / J&J
Trial completion, Enrollment change: A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista (clinicaltrials.gov) - Dec 5, 2016
P4, N=225, Completed, Sponsor: Janssen Korea, Ltd., Korea
Active, not recruiting --> Recruiting Active, not recruiting --> Completed | N=3000 --> 225
- | Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion: Interaction With HIV Antiretroviral Agents (clinicaltrials.gov) - Oct 20, 2016
P1, N=40, Completed, Sponsor: Bayer
Active, not recruiting --> Completed | N=3000 --> 225 Recruiting --> Completed
- ||| Prezista (darunavir) / J&J
Enrollment closed: A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista (clinicaltrials.gov) - Oct 17, 2016
P4, N=3000, Active, not recruiting, Sponsor: Janssen Korea, Ltd., Korea
Recruiting --> Completed Recruiting --> Active, not recruiting
- Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: Interaction With HIV Antiretroviral Agents (clinicaltrials.gov) - Oct 12, 2016
P1, N=40, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2017 --> Oct 2016
- ||||| Prezista (darunavir) / J&J, Prezcobix (darunavir/cobicistat) / Gilead, J&J
New P4 trial: ST.O.RE.: Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta) (clinicaltrials.gov) - Oct 5, 2016
P4, N=300, Active, not recruiting, Sponsor: Janssen-Cilag S.p.A.
- ||| Prezista (darunavir) / J&J
Trial initiation date: TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients (clinicaltrials.gov) - Sep 20, 2016
P2, N=330, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Trial primary completion date: Apr 2017 --> Oct 2016 Initiation date: Dec 2004 --> Oct 2003
- |||| Prezista (darunavir) / J&J
Trial completion: TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients (clinicaltrials.gov) - Sep 19, 2016
P2, N=330, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Initiation date: Dec 2004 --> Oct 2003 No longer recruiting --> Completed
- || Isentress (raltegravir) / Merck (MSD)
Trial primary completion date: RANIA: Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) (clinicaltrials.gov) - Sep 7, 2016
P2, N=100, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
No longer recruiting --> Completed Trial primary completion date: Aug 2016 --> Aug 2017
- Prezista (darunavir) / J&J
Trial primary completion date: VIRECURE: Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection (clinicaltrials.gov) - Aug 17, 2016
P3, N=15, Recruiting, Sponsor: David Garcia Cinca
Trial primary completion date: Aug 2016 --> Aug 2017 Trial primary completion date: Nov 2016 --> Nov 2018
- |||| Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) / Merck (MSD)
Trial primary completion date, Combination therapy: DRIVE-SHIFT: Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (clinicaltrials.gov) - Jul 19, 2016
P3, N=660, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Nov 2016 --> Nov 2018 Trial primary completion date: Mar 2017 --> Jan 2018
- ||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed: Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults (clinicaltrials.gov) - Jul 13, 2016
P3, N=520, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Mar 2017 --> Jan 2018 Recruiting --> Active, not recruiting
- Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment open, HEOR, Cost effectiveness: Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive (clinicaltrials.gov) - Jun 30, 2016
P4, N=150, Recruiting, Sponsor: Juan A. Arnaiz
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion: Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults (clinicaltrials.gov) - Jun 27, 2016
P3, N=158, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Prezista (darunavir) / J&J, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment closed: QuaDar: Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy (clinicaltrials.gov) - Jun 20, 2016
P4, N=10, Active, not recruiting, Sponsor: University of British Columbia
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Prezista (darunavir) / J&J
Trial initiation date: VIRECURE: Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection (clinicaltrials.gov) - Jun 18, 2016
P3, N=15, Recruiting, Sponsor: David Garcia Cinca
Recruiting --> Active, not recruiting Initiation date: Nov 2015 --> Apr 2016
- Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed, Trial primary completion date: HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen (clinicaltrials.gov) - Jun 9, 2016
P4, N=44, Active, not recruiting, Sponsor: Hospital Universitari Vall d'Hebron Research Institute
Initiation date: Nov 2015 --> Apr 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Nov 2016
- |||| lamivudine / Generic mfg.
Trial primary completion date, Head-to-Head: MOBIDIP: Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa (clinicaltrials.gov) - Jun 5, 2016
P3, N=265, Active, not recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Nov 2016 Trial primary completion date: Dec 2016 --> Apr 2016
- Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: Interaction With HIV Antiretroviral Agents (clinicaltrials.gov) - Apr 27, 2016
P1, N=40, Recruiting, Sponsor: Bayer
Trial primary completion date: Dec 2016 --> Apr 2016 Trial primary completion date: Dec 2016 --> Apr 2017
- Prezista (darunavir) / J&J, Intelence (etravirine) / J&J, Isentress (raltegravir) / Merck (MSD)
Enrollment closed, Combination therapy: A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure (clinicaltrials.gov) - Apr 1, 2016
P4, N=545, Active, not recruiting, Sponsor: AIDS Clinical Trials Group
Trial primary completion date: Dec 2016 --> Apr 2017 Recruiting --> Active, not recruiting
- | Zolinza (vorinostat) / Merck (MSD), Selzentry (maraviroc) / ViiV Healthcare
Trial completion: Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection (clinicaltrials.gov) - Mar 30, 2016
P1/2, N=15, Completed, Sponsor: South East Asia Research Collaboration with Hawaii
Recruiting --> Active, not recruiting Active, not recruiting --> Completed